Keywords: gsk, launch, atriance, europe, uk-based, drug, major
GSK to launch Atriance in Europe
Article | 16 July 2007
UK-based drug major GlaxoSmithKline is to launch its drug Atriance (nelarabine), approved for the treatment of T-cell acute lymphoblastic leukemia ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
